Connect Biopharma Holdings Limited (CNTB) Stock Score, Valuation & Financial Research
Connect Biopharma Holdings Limited is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 16/100.
Quick answer for CNTB
Connect Biopharma Holdings Limited currently has a Wall Street Score of 16/100. The stored market price is $1.24. Its financial score is 7/100. Its valuation score is 0/100. The latest WSS change is +0.6 points. These figures are a research snapshot, not a buy or sell recommendation.
What Connect Biopharma Holdings Limited does
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset,
CNTB financial snapshot
- Wall Street Score:
- 16/100
- Current price:
- $1.24
- Market capitalization:
- $78.1M
- Revenue:
- $3.7M
- Net income:
- $-73.6M
- Free cash flow:
- $-51.6M
- Cash:
- $27.0M
- Total debt:
- $596K
- EPS:
- -1.53
- Financial score:
- 7/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is +56.5%.
- Free cash flow is $-51.6M, showing cash burn in the current stored period.
- The balance sheet shows $27.0M of cash versus $596K of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.6 points: CNTB increased 0.6 points because Asset improved by 5.7 points.
- The current research record carries a missing revenue history warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 7/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CNTB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.